missing translation for 'onlineSavingsMsg'
Learn More
  1. Home
  2. Products
  3. Antibodies
  4. Primary Antibodies
  5. All Primary Antibodies
  6. Invitrogen™ Lebrikizumab Recombinant Monoclonal Antibody
  7. 30284790

Invitrogen™ Lebrikizumab Recombinant Monoclonal Antibody

Recombinant Monoclonal Antibody

Brand:  Invitrogen™ MA559536

 View more versions of this product

Product Code. 30284790

  • 1204.00€ / 1mg

Please to purchase this item. Need a web account? Register with us today!

This item is not returnable. View return policy

Beschreibung

Beschreibung

For reconstitution, add sterile, distilled water to achieve a final antibody concentration of 1 mg/mL. Gently shake to solubilize the protein completely. Do not vortex. Reconstituted products should be stored at -80 °.

Lebrikizumab has been used in trials studying the treatment of Asthma, Allergic Asthma, Atopic Dermatitis, Idiopathic Pulmonary Fibrosis, and COPD, Chronic Obstructive Pulmonary Disease.
TRUSTED_SUSTAINABILITY
Spezifikation

Spezifikation

Lebrikizumab Humanized
Recombinant Monoclonal
Unconjugated
MILR1444A; PRO301444
Protein A
RUO
Human
Antibody
IgG4SP
ELISA, Flow Cytometry, Functional Assay, Surface Plasmon Resonance
1 mg/mL
25mM histidine with 8% sucrose, 0.01% Tween 80 and no preservative; pH 6.2
Human
1 mg
Primary
-20°C, Avoid Freeze/Thaw Cycles
Lyophilized
Produktvorschläge

Produktvorschläge

Videos
Sicherheitsdatenblatt (SDS)
Dokumentation

Dokumentation

Product Certifications
Promotions

Promotions

Product Content Correction

Your input is important to us. Please complete this form to provide feedback related to the content on this product.

Product Title

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.

Thank You! Your feedback has been submitted. Fisher Scientific is always working to improve our content for you. We appreciate your feedback.